The FDA accepts GSK's BLA seeking approval of Blenrep combinations for treating relapsed/refractory multiple myeloma. A decision is due on July 23, 2025.

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

Many of you may remember from this column that I have multiple myeloma, or cancer of the bone marrow. In January, I will be headed to UVA hospital for a ...

Helen van Bueren, 77, from Derbyshire, who has Multiple Myeloma, is one of those who has lost her Winter Fuel Payment and ...

Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

The global CAR-T Cell Therapy market size is expected to reach USD 8.92 billion by 2026 growing at a CAGR of 34.5% from 2020 to 2026 according to a new study published by Report Ocean. Request To ...

Am J Health Syst Pharm. 2007;64(17):1799-1807. Despite a similar chemical structure to thalidomide, the toxicity profile of lenalidomide has been shown to be quite different. The major dose ...

Adaptive Biotechnologies posted strong Q3 results, beating expectations and reducing losses. Read why I maintain a Hold ...

Helen van Bueren, 77, from Derbyshire, who has Multiple Myeloma, is one of those who has lost her Winter Fuel Payment. She ...

Maczko said her brother died in 2016 of multiple myeloma and she had other loved ones with cancer. "We started a team years ...